AU750645B2 - Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH - Google Patents

Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH Download PDF

Info

Publication number
AU750645B2
AU750645B2 AU34428/99A AU3442899A AU750645B2 AU 750645 B2 AU750645 B2 AU 750645B2 AU 34428/99 A AU34428/99 A AU 34428/99A AU 3442899 A AU3442899 A AU 3442899A AU 750645 B2 AU750645 B2 AU 750645B2
Authority
AU
Australia
Prior art keywords
carnitine
acid
alkanoyl
camitine
nadh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34428/99A
Other languages
English (en)
Other versions
AU3442899A (en
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau HealthScience SpA
Original Assignee
Sigma Tau HealthScience SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau HealthScience SpA filed Critical Sigma Tau HealthScience SpA
Publication of AU3442899A publication Critical patent/AU3442899A/en
Application granted granted Critical
Publication of AU750645B2 publication Critical patent/AU750645B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU34428/99A 1998-04-17 1999-04-14 Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH Ceased AU750645B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM98A0238 1998-04-17
IT98RM000238A IT1299161B1 (it) 1998-04-17 1998-04-17 Composizione comprendente l-carnitina o un'alcanoil l-carnitina e nadh e/o nadph
PCT/IT1999/000088 WO1999053921A1 (fr) 1998-04-17 1999-04-14 Composition comprenant de la l-carnitine ou un alcanoyl l-carnitine et nadh et/ou nadph

Publications (2)

Publication Number Publication Date
AU3442899A AU3442899A (en) 1999-11-08
AU750645B2 true AU750645B2 (en) 2002-07-25

Family

ID=11405812

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34428/99A Ceased AU750645B2 (en) 1998-04-17 1999-04-14 Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH

Country Status (17)

Country Link
EP (1) EP1071424A1 (fr)
JP (1) JP2002512191A (fr)
KR (1) KR20010042765A (fr)
CN (1) CN1299283A (fr)
AU (1) AU750645B2 (fr)
BR (1) BR9909712A (fr)
CA (1) CA2328331A1 (fr)
EE (1) EE200000601A (fr)
HU (1) HUP0101914A3 (fr)
IL (1) IL139014A0 (fr)
IS (1) IS5663A (fr)
IT (1) IT1299161B1 (fr)
NO (1) NO20005128L (fr)
PL (1) PL343482A1 (fr)
SK (1) SK15442000A3 (fr)
TR (1) TR200002894T2 (fr)
WO (1) WO1999053921A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252309B2 (en) 2000-04-04 2012-08-28 Sigma-Tau Industrie Farmaceutiche Riunite Spa Dietary supplement energy-providing to skeletal muscles
DE10326822A1 (de) * 2003-06-11 2005-01-05 Herzpharma Vita-Check Diagnosegeräte GmbH Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels
MX2009012042A (es) * 2007-05-11 2009-12-01 Sigma Tau Ind Farmaceuti Gel util para el suministro de ingredientes activos cosmeticos.
WO2011022786A1 (fr) * 2009-08-31 2011-03-03 Pharmaqest Pty Ltd Procédés de diagnostic et de traitement du syndrome de fatigue chronique
CN104306390A (zh) * 2014-10-23 2015-01-28 苏州人本药业有限公司 还原型辅酶ⅱ的用途
CN104840479A (zh) * 2015-02-17 2015-08-19 苏州人本药业有限公司 Nadph在制备治疗心脏疾病药物中的应用
ES2786774B2 (es) * 2017-12-22 2022-03-04 Bontac Bio Eng Shenzhen Co Ltd Composición para compuesto de coenzima NADH, preparación y aplicación del mismo.
PL3755160T3 (pl) 2018-04-20 2022-02-14 Pacotrade Ag Urządzenie do rozdrabniania głęboko mrożonych środków spożywczych przygotowanych w formie bloku
CN109170907A (zh) * 2018-08-30 2019-01-11 泓博元生命科技（深圳）有限公司 一种含有nmn的组合物、应用及运动饮料的制备方法
CN109105702A (zh) * 2018-08-30 2019-01-01 泓博元生命科技（深圳）有限公司 一种含有nadh的组合物、应用及能量补充剂的制备方法
CA3115743A1 (fr) * 2018-10-10 2020-04-16 So Ngor Sally LEUNG Composition de produit de sante permettant de compenser un deficit, son procede de preparation et son application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054698A (fr) * 1964-12-04
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
WO1997039749A2 (fr) * 1996-04-25 1997-10-30 Abbott Laboratories Procede de prevention et de traitement de la cachexie et de l'anorexie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
JPH09110708A (ja) * 1995-08-11 1997-04-28 Taisho Pharmaceut Co Ltd 滋養強壮用生薬配合製剤
JPH0959161A (ja) * 1995-08-23 1997-03-04 Taisho Pharmaceut Co Ltd 疲労改善用組成物
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
JPH10175856A (ja) * 1996-10-14 1998-06-30 Taisho Pharmaceut Co Ltd 疲労改善剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054698A (fr) * 1964-12-04
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
WO1997039749A2 (fr) * 1996-04-25 1997-10-30 Abbott Laboratories Procede de prevention et de traitement de la cachexie et de l'anorexie

Also Published As

Publication number Publication date
EE200000601A (et) 2002-04-15
IS5663A (is) 2000-10-13
CA2328331A1 (fr) 1999-10-28
KR20010042765A (ko) 2001-05-25
TR200002894T2 (tr) 2001-01-22
WO1999053921A1 (fr) 1999-10-28
NO20005128L (no) 2000-12-18
SK15442000A3 (sk) 2001-06-11
IT1299161B1 (it) 2000-02-29
HUP0101914A3 (en) 2002-12-28
BR9909712A (pt) 2000-12-26
NO20005128D0 (no) 2000-10-12
JP2002512191A (ja) 2002-04-23
IL139014A0 (en) 2001-11-25
HUP0101914A2 (hu) 2002-03-28
ITRM980238A1 (it) 1999-10-17
ITRM980238A0 (it) 1998-04-17
PL343482A1 (en) 2001-08-27
CN1299283A (zh) 2001-06-13
AU3442899A (en) 1999-11-08
EP1071424A1 (fr) 2001-01-31

Similar Documents

Publication Publication Date Title
EP0973415B1 (fr) Complement nutritionnel destine a faciliter l'adaptation de muscles squelettiques lors d'exercices eprouvants et a lutter contre le surmenage chez des individus astheniques
Abraham et al. Management of fibromyalgia: rationale for the use of magnesium and malic acid
US8747906B2 (en) Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose
US20120053240A1 (en) Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)
AU4575299A (en) Compositions for increasing energy (in vivo)
AU750645B2 (en) Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH
US5994581A (en) Carnitine creatinate
CZ20014077A3 (cs) Doplňková výľiva dodávající energii kosternímu svalstvu a chránící kardiovaskulární systém
CA2400959C (fr) Composition destinee a la prevention et/ou au traitement des maladies vasculaires, comprenant de la l-carnitine de propionyl et la coenzyme q10
MXPA00009983A (en) Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph
US20020002202A1 (en) Use of fumarate salt of L-carnitine or its alkanoyl derivatives in ischaemia
CZ20003831A3 (cs) Přípravek obsahující L-karnitin nebo alkanoyl Lkarnitinu a NADH a/nebo NADPH
AU2001241030A1 (en) Composition for the prevention and/or treatment of vascular diseases, comprising propionyl L-carnitine and coenzyme Q10
WO2023156275A1 (fr) Composition pharmaceutique et médicament comprenant du l-tryptophane, du l-5-hydroxytryptophane et un inhibiteur de dégradation périphérique
MXPA99008999A (en) Nutritional supplement for facilitating skeletal muscle adaptation to strenuous exercise and counteracting defatigation in asthenic individuals
CZ347999A3 (cs) Doplňková výživa pro snazší adaptaci kosterního svalstva vyčerpaného zatěžujícími výkony a paralyzování únavy asthenických jedinců